search
Back to results

The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms

Primary Purpose

HIV Infections

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
HBY 097
Zidovudine
Sponsored by
Hoechst Marion Roussel
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV Infections focused on measuring Drug Therapy, Combination, AIDS-Related Complex, Antiviral Agents, Zidovudine

Eligibility Criteria

13 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria Concurrent Medication: Allowed: Treatment for opportunistic infection that develops on study. Recommended: PCP prophylaxis if CD4 count falls below 200 cells/mm3. Patients must have: HIV infection. CD4 count 200 - 500 cells/mm3. HIV-1 RNA PCR value of 10000 copies/ml or higher. Asymptomatic or mildly symptomatic disease. No past or current AIDS-defining event. Consent of parent or guardian if less than legal age of consent. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Endocrine, hepatic, renal, or gastrointestinal disease. Cardiovascular conduction disease. Concomitant medical illness that may complicate study conduct or interpretation of results. Other factors that may interfere with patient compliance. Concurrent Medication: Excluded: Antiretroviral agents other than study drugs. Oral contraceptives. Cytotoxic chemotherapy. Immunomodulators. Antiproliferative agents. Corticosteroids. Anabolic steroids. Estrogens. Quinoxaline derivatives. Concurrent Treatment: Excluded: Radiation therapy. Patients with the following prior conditions are excluded: History of hypersensitivity to quinoxaline derivatives or intolerance to AZT. History of cardiovascular conduction disease. Prior participation in this study or any study using HBY 097. Recent use of a drug that interferes with drug metabolism, absorption, distribution, or excretion. History of thyroid disease. Prior Medication: Excluded at any time: Prior non-nucleoside reverse transcriptase inhibitors. Excluded within 30 days prior to study entry: Any antiretroviral therapy. Oral contraceptives. Immunomodulating agents such as systemic corticosteroids, interleukins, or interferons. Cytotoxic chemotherapeutic agents. Other investigational drugs. Excluded within 6 months prior to study entry: Immunotherapeutic vaccine. Prior Treatment: Excluded within 30 days prior to study entry: Radiation therapy. An experimental device. Current ethanol or illicit drug abuse.

Sites / Locations

  • Los Angeles County - USC Med Ctr
  • Stanford Univ School of Medicine
  • Georgetown Univ Med Ctr
  • Med College of Georgia
  • New York Univ Med Ctr
  • Houston Clinical Research Network

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 2, 1999
Last Updated
June 23, 2005
Sponsor
Hoechst Marion Roussel
search

1. Study Identification

Unique Protocol Identification Number
NCT00002357
Brief Title
The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms
Official Title
A Multicenter, Randomized, Double-Blinded, Dose-Escalation Study Evaluating the Safety and Antiretroviral Activity of HBY 097 Versus HBY 097 Plus AZT in Patients With Asymptomatic or Mildly Symptomatic HIV Infection
Study Type
Interventional

2. Study Status

Record Verification Date
May 1997
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Hoechst Marion Roussel

4. Oversight

5. Study Description

Brief Summary
To obtain preliminary information on the safety, tolerability, and antiretroviral activity of HBY 097 alone or in combination with zidovudine ( AZT ) versus AZT alone. PER 1/19/96 AMENDMENT: AZT monotherapy arm was eliminated.
Detailed Description
Patients are randomized to receive one of three doses of HBY 097 with or without AZT or AZT alone for 12 weeks (AZT monotherapy arm eliminated per 1/19/96 amendment). All patients at a given dose level of HBY 097 must be enrolled and adequate safety data obtained before escalation in subsequent patients begins. Additional patients are entered at the optimal dose of HBY 097. Patients are evaluated weekly for the first 4 weeks and then every 2 weeks for the next 9 weeks. PER AMENDMENT: Enrollment to the lowest dose cohort is completed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
Drug Therapy, Combination, AIDS-Related Complex, Antiviral Agents, Zidovudine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Masking
Double
Enrollment
144 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
HBY 097
Intervention Type
Drug
Intervention Name(s)
Zidovudine

10. Eligibility

Sex
All
Minimum Age & Unit of Time
13 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Treatment for opportunistic infection that develops on study. Recommended: PCP prophylaxis if CD4 count falls below 200 cells/mm3. Patients must have: HIV infection. CD4 count 200 - 500 cells/mm3. HIV-1 RNA PCR value of 10000 copies/ml or higher. Asymptomatic or mildly symptomatic disease. No past or current AIDS-defining event. Consent of parent or guardian if less than legal age of consent. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Endocrine, hepatic, renal, or gastrointestinal disease. Cardiovascular conduction disease. Concomitant medical illness that may complicate study conduct or interpretation of results. Other factors that may interfere with patient compliance. Concurrent Medication: Excluded: Antiretroviral agents other than study drugs. Oral contraceptives. Cytotoxic chemotherapy. Immunomodulators. Antiproliferative agents. Corticosteroids. Anabolic steroids. Estrogens. Quinoxaline derivatives. Concurrent Treatment: Excluded: Radiation therapy. Patients with the following prior conditions are excluded: History of hypersensitivity to quinoxaline derivatives or intolerance to AZT. History of cardiovascular conduction disease. Prior participation in this study or any study using HBY 097. Recent use of a drug that interferes with drug metabolism, absorption, distribution, or excretion. History of thyroid disease. Prior Medication: Excluded at any time: Prior non-nucleoside reverse transcriptase inhibitors. Excluded within 30 days prior to study entry: Any antiretroviral therapy. Oral contraceptives. Immunomodulating agents such as systemic corticosteroids, interleukins, or interferons. Cytotoxic chemotherapeutic agents. Other investigational drugs. Excluded within 6 months prior to study entry: Immunotherapeutic vaccine. Prior Treatment: Excluded within 30 days prior to study entry: Radiation therapy. An experimental device. Current ethanol or illicit drug abuse.
Facility Information:
Facility Name
Los Angeles County - USC Med Ctr
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Facility Name
Stanford Univ School of Medicine
City
Stanford
State/Province
California
ZIP/Postal Code
943055107
Country
United States
Facility Name
Georgetown Univ Med Ctr
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20007
Country
United States
Facility Name
Med College of Georgia
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30912
Country
United States
Facility Name
New York Univ Med Ctr
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Houston Clinical Research Network
City
Houston
State/Province
Texas
ZIP/Postal Code
77006
Country
United States

12. IPD Sharing Statement

Learn more about this trial

The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms

We'll reach out to this number within 24 hrs